The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer
J. N. Ingle
Consultant or Advisory Role - Pfizer (U)
J. Ales-Martinez
Research Funding - Pfizer
Other Remuneration - Pfizer
A. Cheung
No relevant relationships to disclose
R. T. Chlebowski
No relevant relationships to disclose
J. Wactawski-Wende
Research Funding - Pfizer
A. McTiernan
Consultant or Advisory Role - Novartis; Proctor and Gamble
Stock Ownership - Merck
J. Robbins
No relevant relationships to disclose
K. Johnson
Research Funding - Pfizer
L. Martin
No relevant relationships to disclose
E. Winquist
No relevant relationships to disclose
G. Sarto
No relevant relationships to disclose
J. E. Garber
No relevant relationships to disclose
C. J. Fabian
No relevant relationships to disclose
P. Pujol
No relevant relationships to disclose
E. Maunsell
No relevant relationships to disclose
P. Farmer
No relevant relationships to disclose
K. A. Gelmon
Consultant or Advisory Role - Pfizer
D. Tu
No relevant relationships to disclose
H. Richardson
Research Funding - Pfizer